William Blair Comments on Teladoc Inc’s FY2017 Earnings (TDOC)
Teladoc Inc (NYSE:TDOC) – Investment analysts at William Blair decreased their FY2017 earnings per share estimates for shares of Teladoc in a research note issued to investors on Tuesday. William Blair analyst R. Daniels now expects that the health services provider will earn ($1.55) per share for the year, down from their prior estimate of ($1.54). William Blair also issued estimates for Teladoc’s Q4 2017 earnings at ($0.41) EPS, Q1 2018 earnings at ($0.48) EPS, Q2 2018 earnings at ($0.34) EPS, Q3 2018 earnings at ($0.32) EPS, Q4 2018 earnings at ($0.27) EPS, FY2018 earnings at ($1.40) EPS and FY2019 earnings at ($0.81) EPS.
Teladoc (NYSE:TDOC) last released its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 29.70% and a negative net margin of 45.64%. The business had revenue of $68.70 million during the quarter, compared to the consensus estimate of $67.53 million. During the same period in the previous year, the company posted ($0.33) EPS. The company’s revenue for the quarter was up 112.0% compared to the same quarter last year.
Several other research analysts have also recently issued reports on the company. KeyCorp reissued a “buy” rating and issued a $41.00 price target on shares of Teladoc in a research note on Wednesday. Citigroup began coverage on Teladoc in a research note on Thursday, January 4th. They issued a “buy” rating for the company. ValuEngine raised Teladoc from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Deutsche Bank started coverage on Teladoc in a research note on Friday, December 8th. They issued a “buy” rating and a $39.00 price target for the company. Finally, CIBC reaffirmed an “outperform” rating and set a $45.00 target price (up previously from $40.00) on shares of Teladoc in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $39.31.
Teladoc (NYSE TDOC) opened at $32.65 on Friday. Teladoc has a 52 week low of $15.65 and a 52 week high of $38.40. The stock has a market capitalization of $1,980.00 and a price-to-earnings ratio of -22.52. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83.
In related news, CEO Jason N. Gorevic sold 20,000 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $32.10, for a total transaction of $642,000.00. Following the completion of the transaction, the chief executive officer now owns 838,261 shares of the company’s stock, valued at $26,908,178.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $32.99, for a total value of $3,299,000.00. Following the transaction, the chief executive officer now directly owns 718,261 shares of the company’s stock, valued at approximately $23,695,430.39. The disclosure for this sale can be found here. Insiders have sold 210,000 shares of company stock valued at $6,889,350 in the last ninety days. Company insiders own 4.47% of the company’s stock.
Several large investors have recently added to or reduced their stakes in TDOC. ETF Managers Group LLC acquired a new position in shares of Teladoc in the 2nd quarter valued at $104,000. Pacad Investment Ltd. acquired a new position in shares of Teladoc in the 2nd quarter valued at $135,000. Fred Alger Management Inc. acquired a new position in shares of Teladoc in the 2nd quarter valued at $139,000. Ameritas Investment Partners Inc. boosted its position in shares of Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after purchasing an additional 2,707 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of Teladoc in the 2nd quarter valued at $166,000.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.